Jilin Provincial Tumor Hospital

Changchun, China

Jilin Provincial Tumor Hospital

Changchun, China
Time filter
Source Type

Gong J.,Peking University | Hu B.,Anhui Provincial Hospital | Zhang X.,Peking University | Zhang F.,Suzhou Kowloon Hospital | And 15 more authors.
Oncologist | Year: 2014

Background. The efficacy and toxicity of paclitaxel plus capecitabine (PX) as first-line treatment in advanced gastric cancer (AGC) was evaluated. Methods. Patients with previously untreated AGC were included. PX was given every 3 weeks until a maximum of six cycles or progression. Capecitabine monotherapy was continued for patients without disease progression. The primary endpoint was progression-free survival, and secondary endpoints were objective response rate, overall survival (OS), and safety. Results. Overall, 194 patients were treated per protocol and one patient was excluded because of allergy to paclitaxel. Response was evaluated in 175 patients, with an objective response rate of 34.8%. After a median follow-up of 33.2 months, disease progression was observed in 141 patients, 137 died, and 16 were lost to follow-up, with progression-free survival of 188 days and OS of 354 days. In multivariate Cox regression analysis, no factor remained an independent predictor of OS. Forty-five patients who received capecitabine monotherapy after PX had longer OS (531 days). Adverse events were mild (Fig. 1), and the most common grade 3-4 toxicities were leucopenia and neutropenia. Conclusion. PX as a first-line treatment has promising efficacy in AGC. Based on these data, a phase III study has been launched for further investigation. © AlphaMed Press 2014.

Li J.,Fudan University | Qin S.,Chinese People's Liberation Army | Xu R.,Sun Yat Sen University | Yau T.C.C.,University of Hong Kong | And 16 more authors.
The Lancet Oncology | Year: 2015

Background: In the international randomised phase 3 CORRECT trial (. NCT01103323), regorafenib significantly improved overall survival versus placebo in patients with treatment-refractory metastatic colorectal cancer. Of the 760 patients in CORRECT, 111 were Asian (mostly Japanese). This phase 3 trial was done to assess regorafenib in a broader population of Asian patients with refractory metastatic colorectal cancer than was studied in CORRECT. Methods: In this randomised, double-blind, placebo-controlled, parallel-group, phase 3 trial done in 25 hospitals in mainland China, Hong Kong, South Korea, Taiwan, and Vietnam, we recruited Asian patients aged 18 years or older with progressive metastatic colorectal cancer who had received at least two previous treatment lines or were unable to tolerate standard treatments. Patients had to have an Eastern Cooperative Oncology Group performance status of 0 or 1, life expectancy of at least 3 months, and adequate bone marrow, liver, and renal function, without other uncontrolled medical disorders. We randomly allocated patients (2:1; with a computer-generated unicentric randomisation list [prepared by the study funder] and interactive voice response system; block size of six; stratified by metastatic site [single vs multiple organs] and time from diagnosis of metastatic disease [<18 months vs ≥18 months]) to receive oral regorafenib 160 mg once daily or placebo on days 1-21 of each 28 day cycle; patients in both groups were also to receive best supportive care. Participants, investigators, and the study funder were masked to treatment assignment. The primary endpoint was overall survival, and we analysed data on an intention-to-treat basis. This trial is registered with ClinicalTrials.gov, number NCT01584830. Findings: Between April 29, 2012, and Feb 6, 2013, we screened 243 patients and randomly assigned 204 patients to receive either regorafenib (136 [67%]) or placebo (68 [33%]). After a median follow-up of 7·4 months (IQR 4·3-12·2), overall survival was significantly better with regorafenib than it was with placebo (hazard ratio 0·55, 95% CI 0·40-0·77, one-sided p=0·00016; median overall survival 8·8 months [95% CI 7·3-9·8] in the regorafenib group vs 6·3 months [4·8-7·6] in the placebo group). Drug-related adverse events occurred in 132 (97%) of 136 regorafenib recipients and 31 (46%) of 68 placebo recipients. The most frequent grade 3 or higher regorafenib-related adverse events were hand-foot skin reaction (22 [16%] of 136 patients in the regorafenib group vs none in the placebo group), hypertension (15 [11%] vs two [3%] of 68 patients in the placebo group), hyperbilirubinaemia (nine [7%] vs one [1%]), hypophosphataemia (nine [7%] vs none), alanine aminotransferase concentration increases (nine [7%] vs none), aspartate aminotransferase concentration increases (eight [6%] vs none), lipase concentration increases (six [4%] vs one [1%]), and maculopapular rash (six [4%] vs none). Drug-related serious adverse events occurred in 12 (9%) patients in the regorafenib group and three (4%) in the placebo group. Interpretation: This phase 3 trial is the second to show an overall survival benefit with regorafenib compared with placebo in patients with treatment-refractory metastatic colorectal cancer, substantiating the role of regorafenib as an important treatment option for patients whose disease has progressed after standard treatments. In this trial, preceding standard treatments did not necessarily include targeted treatments. Adverse events were generally consistent with the known safety profile of regorafenib in this setting. Funding: Bayer HealthCare Pharmaceuticals. © 2015 Elsevier Ltd.

Dong Y.,Jilin Provincial Tumor Hospital | Wang X.,Jilin University | Yang Y.-W.,Jilin Provincial Tumor Hospital | Liu Y.-J.,Jilin University
Cellular and Molecular Biology | Year: 2017

Many studies have been carried out to examine whether there is an association between CDKN2A polymorphisms and cancer risk, but the results from these studies were controversial. In the present study, we performed a meta-analysis to clarify whether there is an association of CDKN2A polymorphisms and cancer risk. Published reports were searched in PubMed and Google Scholar. ORs with 95% CIs were calculated in the dominant models. Twenty six case-control studies that met the inclusion criteria were included in the final meta-analysis. Overall, we found that rs3731249, rs11515, and rs3088440 polymorphisms were not associated with cancer risk (OR=1.27, 95%CI: 0.79-2.03; OR=0.91, 95%CI: 0.79-1.03; OR=1.02, 95%CI: 0.95-1.09). However, CDKN2A rs3731249 polymorphism was significantly associated with ovarian cancer risk (OR=0.78, 95%CI: 0.65-0.95). A significant association was observed in Asian with rs11515 polymorphism (OR=0.48, 95%CI: 0.28-0.83). This meta-analysis shows that CDKN2A rs3731249 polymorphism was significantly associated with ovarian cancer risk. In addition, CDKN2A rs11515 polymorphism might associate with cancer risk in Asians. © 2017 by the C.M.B. Association. All rights reserved.

Shen E.-H.,Jilin University | Du J.,Jilin Provincial Tumor Hospital | Wang L.-H.,Jilin University | Zhang J.-F.,Jilin University | And 2 more authors.
Journal of Xi'an Jiaotong University (Medical Sciences) | Year: 2017

Objective: To study the inhibitory effect and mechanism of citrusinol on proliferation of human hepatocellular carcinoma cells HepG2. Methods: The inhibitory rate of HepG2 cells cultured in vitro was measured by MTT assay. The morphology and distribution of the cells were observed by HE and acridine orange staining. The cell division cycle was detected by flow cytometry. The expression of F-actin protein was observed by fluorescent chromogenic method. Results: Citrusinol could inhibit the growth of HepG2 cells, and the IC50 of the inhibitory rate was 76.46 μmol/L. Citrusinol could make the HepG2 cells shrink, arrest the cell division cycle to G2/M, and inhibit the expression of F-actin. Conclusion: Citrusinol can prevent cell proliferation by arresting cell division cycle in G2/M phase and inhibiting the formation of cytoskeleton, thus inhibiting the growth of G2/M. © 2017, Editorial Board of Journal of Xi'an Jiaotong University (Medical Sciences). All right reserved.

Ge L.,Jilin University | Li D.-S.,Jilin University | Chen F.,Jilin Provincial Tumor Hospital | Feng J.-D.,Jilin Province Hospital of Traditional Chinese Medicine | And 2 more authors.
International Journal of Oncology | Year: 2017

Gastric cancer is one of the common malignant diseases. The poor treatment outcome is mainly due to chemotherapeutic resistance. Therefore, it is important to determine the molecular mechanism of drug resistance in gastric cancer. To explore the mechanisms of cisplatin resistance in gastric cancer cells, several approaches were performed including MTT assay, real-time RT-PCR, western blot analysis, migration and invasion assays, wound healing assay, and transfection. We found that cisplatin-resistant (CR) gastric cancer cells acquired epithelial-mesenchymal transition (EMT) phenotype. The CR cells with EMT features obtained higher migratory and invasive activities. Moreover, we observed that TAZ was highly expressed in CR cells. Consistently, depletion of TAZ caused partial reversal of EMT to MET in CR cells. Our results suggest that TAZ plays a pivotal role in CR-induced EMT. Targeting TAZ could be a potential therapeutic strategy for gastric cancer.

Wang X.,Jilin University | Wang Z.,Jilin University | Liu B.,Jilin University | Jin Y.,Yanbian University | Zhang D.,Jilin Provincial Tumor Hospital
Journal of Jilin University Medicine Edition | Year: 2016

Objective: To understand the typing of Rh system phenotypes and analyze the positive rate of irregular antibody in Rh system, and to provide basis for blood transfusion of the elderly patients in clinic. Methods: A total of 587 elderly blood tranfusion candidates were included. Microcolumn gel test was applied to detect the antigens of Rh system and identify the irregular antibody in Rh system. Results: There were 7 kinds of Rh blood group phenotypes with postive expression of RhD in 587 patients; the positive rates of irregular antibodies from high to low were CCDEE 38. 7% (227/587), CcDEe 34. 8% (204/587), CcDee 12. 4% (73/587), ccDEE 8. 7% (51/ 587), ccDEe 4. 6% (27/587) and CCDEe 0. 7% (4/587), ccDee 0.2% (1/587). There were 6 kinds of irregylar antibodies in 587 patients; the positive rate was 1.02%, including 4 cases of Anti-E (66. 67%), 1 case of Anti-c (16.67%), 1 case of anti-M (16.67%). The postive rate of irregular antibody in the patients with blood transfution history and pregnancy history (2. 65% , 51/89) was higher than those without blood transfusion history or pregnancy history 0. 25% , 13/98) (χ 2=5. 11, P<0.05). There were no significant differences of the positive rates of irregular antibody between different nationalities =0.10, P > 0.05). Conclusion: The irregular antibody of Rh system is the major antibody in the eldery blood transtusion candidates. The detection of typing of Rh system phenotypes and identification of irregular antibodies in the patients with blood transfusion history and pregnancy history should be performed to ensure the safty of blood transfusion.

PubMed | Shanghai JiaoTong University and Jilin Provincial Tumor Hospital
Type: Evaluation Studies | Journal: Zhongguo fei ai za zhi = Chinese journal of lung cancer | Year: 2014

To discuss the clinical application of mediastinoscopy in the differential diagnosis and preoperative staging on lung cancer.A total of 361 cases of patients were included in the study, of which 162 cases were undiagnosed mediastinal tumor patients before operation, and 199 patients were suspected or diagnosed with lung cancer or mediastinal lymph nodes enlargment(short diameter 1.0 cm). All patients underwent surgery, including 308 cases standard cervical mediastinoscopy (SCM) , 53 cases parasternal mediastinoscopy (PM).Taking pathology diagnosis as the gold standard, the mediastinoscopy diagnostic accuracy, sensitivity, specificity, positive predictive value, negative predictive value are 98.11%, 97.62%, 100%, 100%, 91.67% and 98.28%, 98.03%, a 100%, 100%, 100% to mediastinal masses and mediastinal lymph node metastasis of lung cancer. Total seven cases suffered from complications of surgery-related, the complication rate was 1.93 percent (P<0.05).The trauma of the mediastinoscopy is slight, which is safe, reliable, able to take in sufficient tissue quantities. Mediastinoscopy is highly helpful not only in diagnostic of mediastinal mass, but also in the differential diagnosis of lung cancer, and its an important method and the gold standard of preoperative staging on lung cancer.

Wang Y.,Northeast Normal University | Ju Z.,Northeast Normal University | Ju Z.,University of Oklahoma | Cao B.,University of Oklahoma | And 8 more authors.
ACS Nano | Year: 2015

Candida albicans (C. albicans) infection causes high mortality rates within cancer patients. Due to the low sensitivity of the current diagnosis systems, a new sensitive detection method is needed for its diagnosis. Toward this end, here we exploited the capability of genetically displaying two functional peptides, one responsible for recognizing the biomarker for the infection (antisecreted aspartyl proteinase 2 IgG antibody) in the sera of cancer patients and another for binding magnetic nanoparticles (MNPs), on a single filamentous fd phage, a human-safe bacteria-specific virus. The resultant phage is first decorated with MNPs and then captures the biomarker from the sera. The phage-bound biomarker is then magnetically enriched and biochemically detected. This method greatly increases the sensitivity and specificity of the biomarker detection. The average detection time for each serum sample is only about 6 h, much shorter than the clinically used gold standard method, which takes about 1 week. The detection limit of our nanobiotechnological method is approximately 1.1 pg/mL, about 2 orders of magnitude lower than that of the traditional antigen-based method, opening up a new avenue to virus-based disease diagnosis. © 2015 American Chemical Society.

Zhu J.,Jilin Provincial Tumor Hospital | Ma L.,Jilin Provincial Tumor Hospital | Cheng Y.,Jilin Provincial Tumor Hospital
Chinese-German Journal of Clinical Oncology | Year: 2010

Objective: This study was aimed to research the feasibility of ATP-bioluminescence assay (ATP-TCA) guiding the treatment on recurrent non-small cell lung cancer (NSCLC) combined with malignant pleural effusion. Methods: We collected 30 pleural fluid samples which were approved to be positive by cytology from recurrent NSCLC patients. These cells were cocultured with chemotherapy medicines, single agent or drugs combination. Five drug concentrations, two parallel holes were examined in vitro for 4 days, the results were measured by adding luciferase-fluorescein working system and luminescence analyzer. We applied chemotherapy medicines according to the results in vitro of ATP-TCA. Results: There were differences among drug sensitivities of individuals. All the samples could be evaluated. Effective single drugs included cisplatinum, mitomycin C, doxorubicin, and pemetrexed disodium; sensitive drugs in the combination therapy were gemcitabine plus cisplatin, vinorelbine plus cisplatin, paclitaxel plus cisplatin, docetaxel plus cisplatin, and mitomycin C, vindesine plus cisplatin, in which gemcitabine + cisplatin (GEM + DDP) in vitro was the most efficient program. Conclusion: ATP-TCA in vitro sensitivity assay is rapid, reliable, and simple to guide the treatment of recurrent NSCLC with malignant pleural effusion, and can help clinicians to make the individual chemotherapy program. © 2010 Springer-Verlag Berlin Heidelberg.

PubMed | Jilin Provincial Tumor Hospital
Type: Journal Article | Journal: Zhongguo fei ai za zhi = Chinese journal of lung cancer | Year: 2014

Small cell lung cancer accounts for about 15%-25% of lung cancer, although the new chemotherapy drugs and radiation technology are continuously progressing, but the prognosis is still poor. To explore the prognostic factor of small cell lung cancer (SCLC), we study the correlation between effect, prognosis and TNM stage, various treatment mode.We collected 91 Limited-disease-SCLC patients data From 2006 to 2012. The data were reviewed retrospectively and restaged as I, II, IIIa and IIIb stage groups according to the clinical staging in the seventh edition of the tumor. We compare the progression-free survival (FPS) and overall survival (OS). Survival analysis was evaluated by Kaplan-Meier and multivariate analysis was performed by Cox proportional hazards model.In the whole group, patients achieved complete response and partial response, exhibited an RR of 93.4%. The median PFS was 14.25 months of which, 22.03 months in patients in stage I, 15.97 months in stage II, 11.99 months in stage IIIa and 10.5 months in stage IIIb (P<0.05). The median overall survival (OS) was 19.56 months of which, 33.38 months in patients in stage I, 22.07 months in stage II, 16.0 months in stage IIIa and 15.52 months in stage IIIb (P<0.05). Patients of stage IIIa and IIIb have longer survival time in earlier radiation groups then that of later radiation groups. Univariate analysis indicate stage of TNM, the pattern of radiation therapy and chemotherapy cycles before radiation therapy were significantly related to the survival in SCLC. Multivariate analysis showed that stage of TNM, ECOG (Eastern Cooperative Oncology Group) performance status, pattern of radiation therapy and cycle numbers of chemotherapy before radiation were factors correlated with survival.The stage of TNM may become beneficial prognostic factors in the treatment of LD-SCLC. The time of radiation therapy in stage IIIa and IIIb is of worth further investigation.

Loading Jilin Provincial Tumor Hospital collaborators
Loading Jilin Provincial Tumor Hospital collaborators